{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T02:06:02Z","timestamp":1793066762847,"version":"4.5.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"an independent research"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Cell Research"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.yexcr.2015.07.018","type":"journal-article","created":{"date-parts":[[2015,7,21]],"date-time":"2015-07-21T19:54:16Z","timestamp":1437508456000},"page":"68-75","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Effects of cilengitide in osteoclast maturation and behavior"],"prefix":"10.1016","volume":"337","author":[{"given":"Anastasia","family":"Chill\u00e0","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Bianconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nisha","family":"Geetha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Dorda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Poettler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Unseld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Despoina","family":"Sykoutri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt","family":"Redlich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph C.","family":"Zielinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald W.","family":"Prager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yexcr.2015.07.018_bib1","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/978-1-61779-166-6_22","article-title":"Overview: studying integrins in vivo","volume":"757","author":"Lowell","year":"2012","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.yexcr.2015.07.018_bib2","doi-asserted-by":"crossref","first-page":"154","DOI":"10.7150\/thno\/v01p0154","article-title":"Integrin targeted therapeutics","volume":"1","author":"Millard","year":"2011","journal-title":"Theranostics"},{"issue":"4","key":"10.1016\/j.yexcr.2015.07.018_bib3","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/nrm2871","article-title":"The final steps of integrin activation: the end game","volume":"11","author":"Shattil","year":"2010","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"10","key":"10.1016\/j.yexcr.2015.07.018_bib4","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/nrm1490","article-title":"Integrin signalling during tumour progression","volume":"5","author":"Guo","year":"2004","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"5","key":"10.1016\/j.yexcr.2015.07.018_bib5","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.ceb.2006.08.011","article-title":"Integrin-regulated FAK-Src signaling in normal and cancer cells","volume":"18","author":"Mitra","year":"2006","journal-title":"Curr. Opin. Cell Biol."},{"issue":"4","key":"10.1016\/j.yexcr.2015.07.018_bib6","doi-asserted-by":"crossref","first-page":"E83","DOI":"10.1038\/ncb0402-e83","article-title":"Sensing the environment: a historical perspective on integrin signal transduction","volume":"4","author":"Miranti","year":"2002","journal-title":"Nat. Cell Biol."},{"issue":"3","key":"10.1016\/j.yexcr.2015.07.018_bib7","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/cdd.2012.138","article-title":"Regulation of endodermal differentiation of human embryonic stem cells through integrin-ECM interactions","volume":"20","author":"Brafman","year":"2013","journal-title":"Cell Death Differ."},{"issue":"1","key":"10.1016\/j.yexcr.2015.07.018_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.scr.2010.09.005","article-title":"Stem cell integrins: implications for ex-vivo culture and cellular therapies","volume":"6","author":"Prowse","year":"2011","journal-title":"Stem Cell Res."},{"issue":"22","key":"10.1016\/j.yexcr.2015.07.018_bib9","doi-asserted-by":"crossref","first-page":"16737","DOI":"10.1016\/S0021-9258(19)85479-0","article-title":"Biochemical characterization of human osteoclast integrins. Osteoclasts express alpha v beta 3, alpha 2 beta 1, and alpha v beta 1 integrins","volume":"268","author":"Nesbitt","year":"1993","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.yexcr.2015.07.018_bib10","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1046\/j.1365-2141.2003.04530.x","article-title":"Upregulation of osteoclast alpha2beta1 integrin compensates for lack of alphavbeta3 vitronectin receptor in Iraqi-Jewish-type Glanzmann thrombasthenia","volume":"122","author":"Horton","year":"2003","journal-title":"Br. J. Haematol."},{"issue":"4","key":"10.1016\/j.yexcr.2015.07.018_bib11","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S8756-3282(96)00223-2","article-title":"Beta 1 integrins and osteoclast function: involvement in collagen recognition and bone resorption","volume":"19","author":"Helfrich","year":"1996","journal-title":"Bone"},{"key":"10.1016\/j.yexcr.2015.07.018_bib12","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1755-1536-5-4","article-title":"Endothelial progenitor cells and integrins: adhesive needs","volume":"5","author":"Caiado","year":"2012","journal-title":"Fibrogenesis Tissue Repair"},{"issue":"1","key":"10.1016\/j.yexcr.2015.07.018_bib13","doi-asserted-by":"crossref","first-page":"a006478","DOI":"10.1101\/cshperspect.a006478","article-title":"alphaV integrins in angiogenesis and cancer","volume":"1","author":"Weis","year":"2011","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.yexcr.2015.07.018_bib14","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1749-6632.2009.05245.x","article-title":"Integrins, growth factors, and the osteoclast cytoskeleton","volume":"1192","author":"Zou","year":"2010","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"1","key":"10.1016\/j.yexcr.2015.07.018_bib15","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00109-012-0974-0","article-title":"Roles of Wnt signals in bone resorption during physiological and pathological states","volume":"91","author":"Maeda","year":"2013","journal-title":"J. Mol. Med. (Berl)"},{"issue":"70","key":"10.1016\/j.yexcr.2015.07.018_bib16","first-page":"201","article-title":"Osteoclasts: malefactors of disease and targets for treatment","volume":"13","author":"Edwards","year":"2012","journal-title":"Discov. Med."},{"key":"10.1016\/j.yexcr.2015.07.018_bib17","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.molmed.2014.06.001","article-title":"Osteoclasts: more than 'bone eaters'","volume":"20","author":"Charles","year":"2014","journal-title":"Trends Mol. Med."},{"issue":"1","key":"10.1016\/j.yexcr.2015.07.018_bib18","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nrc2748","article-title":"Integrins in cancer: biological implications and therapeutic opportunities","volume":"10","author":"Desgrosellier","year":"2010","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.yexcr.2015.07.018_bib19","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.canlet.2013.10.019","article-title":"Roles for GP IIb\/IIIa and alphavbeta3 integrins in MDA-MB-231 cell invasion and shear flow-induced cancer cell mechanotransduction","volume":"344","author":"Zhao","year":"2014","journal-title":"Cancer Lett."},{"issue":"16","key":"10.1016\/j.yexcr.2015.07.018_bib20","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1021\/jm970832g","article-title":"N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists","volume":"42","author":"Dechantsreiter","year":"1999","journal-title":"J. Med. Chem."},{"issue":"10","key":"10.1016\/j.yexcr.2015.07.018_bib21","doi-asserted-by":"crossref","first-page":"753","DOI":"10.2174\/187152010794728639","article-title":"Cilengitide: the first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation","volume":"10","author":"Mas-Moruno","year":"2010","journal-title":"Anticancer Agents Med. Chem."},{"issue":"5","key":"10.1016\/j.yexcr.2015.07.018_bib22","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1007\/s00066-014-0600-x","article-title":"The effect of cilengitide in combination with irradiation and chemotherapy in head and neck squamous cell carcinoma cell lines","volume":"190","author":"Heiduschka","year":"2014","journal-title":"Strahlenther Onkol."},{"issue":"3","key":"10.1016\/j.yexcr.2015.07.018_bib23","doi-asserted-by":"crossref","first-page":"e90374","DOI":"10.1371\/journal.pone.0090374","article-title":"Cilengitide inhibits attachment and invasion of malignant pleural mesothelioma cells through antagonism of integrins alphavbeta3 and alphavbeta5","volume":"9","author":"Cheng","year":"2014","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.yexcr.2015.07.018_bib24","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1016\/j.ijrobp.2006.04.036","article-title":"Integrin alpha v beta 3 antagonist Cilengitide enhances efficacy of radiotherapy in endothelial cell and non-small-cell lung cancer models","volume":"65","author":"Albert","year":"2006","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"8","key":"10.1016\/j.yexcr.2015.07.018_bib25","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1007\/s00405-014-2918-5","article-title":"Cilengitide, a small molecule antagonist, targeted to integrin alphanu inhibits proliferation and induces apoptosis of laryngeal cancer cells in vitro","volume":"271","author":"Wang","year":"2014","journal-title":"Eur. Arch. Otorhinolaryngol."},{"key":"10.1016\/j.yexcr.2015.07.018_bib26","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1186\/1748-717X-8-246","article-title":"In vitro study of combined cilengitide and radiation treatment in breast cancer cell lines","volume":"8","author":"Lautenschlaeger","year":"2013","journal-title":"Radiat. Oncol."},{"issue":"11","key":"10.1016\/j.yexcr.2015.07.018_bib27","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1002\/ijc.24240","article-title":"Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency","volume":"124","author":"Mikkelsen","year":"2009","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.yexcr.2015.07.018_bib28","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/1756-9966-27-86","article-title":"Cilengitide induces cellular detachment and apoptosis in endothelial and glioma cells mediated by inhibition of FAK\/src\/AKT pathway","volume":"27","author":"Oliveira-Ferrer","year":"2008","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"16","key":"10.1016\/j.yexcr.2015.07.018_bib29","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1200\/JCO.2009.26.6650","article-title":"Phase I\/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma","volume":"28","author":"Stupp","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.yexcr.2015.07.018_bib30","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/S1470-2045(14)70379-1","article-title":"Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial","volume":"15","author":"Stupp","year":"2014","journal-title":"Lancet Oncol."},{"issue":"7","key":"10.1016\/j.yexcr.2015.07.018_bib31","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S0959-8049(03)00057-1","article-title":"Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours","volume":"39","author":"Eskens","year":"2003","journal-title":"Eur. J. Cancer"},{"issue":"4","key":"10.1016\/j.yexcr.2015.07.018_bib32","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/nm.1941","article-title":"Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors","volume":"15","author":"Reynolds","year":"2009","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.yexcr.2015.07.018_bib33","first-page":"843","article-title":"Cilengitide inhibits metastatic bone colonization in a nude rat model","volume":"26","author":"Bretschi","year":"2011","journal-title":"Oncol. Rep."},{"issue":"10","key":"10.1016\/j.yexcr.2015.07.018_bib34","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1002\/ijc.25563","article-title":"Cilengitide inhibits progression of experimental breast cancer bone metastases as imaged noninvasively using VCT, MRI and DCE-MRI in a longitudinal in vivo study","volume":"128","author":"Bauerle","year":"2011","journal-title":"Int. J. Cancer"},{"issue":"2","key":"10.1016\/j.yexcr.2015.07.018_bib35","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.molonc.2010.01.002","article-title":"Targeting of VEGF-dependent transendothelial migration of cancer cells by bevacizumab","volume":"4","author":"Prager","year":"2010","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.yexcr.2015.07.018_bib36","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1136\/annrheumdis-2013-eular.602","article-title":"THU0074 AVB3 integrin inhibition with cilengitide both prevents and treats collagen induced arthritis","volume":"72","author":"Sykoutri","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.yexcr.2015.07.018_bib37","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1186\/1471-2407-11-293","article-title":"Differences in integrin expression and signaling within human breast cancer cells","volume":"11","author":"Taherian","year":"2011","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.yexcr.2015.07.018_bib38","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1172\/JCI8905","article-title":"Mice lacking beta3 integrins are osteosclerotic because of dysfunctional osteoclasts","volume":"105","author":"McHugh","year":"2000","journal-title":"J. Clin. Investig."},{"issue":"49","key":"10.1016\/j.yexcr.2015.07.018_bib39","doi-asserted-by":"crossref","first-page":"47366","DOI":"10.1074\/jbc.M208284200","article-title":"U0126 and PD98059, specific inhibitors of MEK, accelerate differentiation of RAW264.7 cells into osteoclast-like cells","volume":"277","author":"Hotokezaka","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"7","key":"10.1016\/j.yexcr.2015.07.018_bib40","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1073\/pnas.96.7.3540","article-title":"Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand","volume":"96","author":"Hsu","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"8","key":"10.1016\/j.yexcr.2015.07.018_bib41","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/nrc867","article-title":"Metastasis to bone: causes, consequences and therapeutic opportunities","volume":"2","author":"Mundy","year":"2002","journal-title":"Nat. Rev. Cancer"},{"issue":"6","key":"10.1016\/j.yexcr.2015.07.018_bib42","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1634\/theoncologist.5-6-463","article-title":"Management of bone metastases","volume":"5","author":"Coleman","year":"2000","journal-title":"Oncologist"},{"issue":"10","key":"10.1016\/j.yexcr.2015.07.018_bib43","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1002\/cncr.10522","article-title":"The clinical use of bone resorption markers in patients with malignant bone disease","volume":"94","author":"Coleman","year":"2002","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.yexcr.2015.07.018_bib44","doi-asserted-by":"crossref","first-page":"5821","DOI":"10.1158\/0008-5472.CAN-06-4499","article-title":"Tumor alphavbeta3 integrin is a therapeutic target for breast cancer bone metastases","volume":"67","author":"Zhao","year":"2007","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.yexcr.2015.07.018_bib45","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1023\/A:1025461507027","article-title":"Inhibition of alpha(v)beta3 integrin reduces angiogenesis, bone turnover, and tumor cell proliferation in experimental prostate cancer bone metastases","volume":"20","author":"Nemeth","year":"2003","journal-title":"Clin. Exp. Metastasis"},{"issue":"3","key":"10.1016\/j.yexcr.2015.07.018_bib46","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1007\/s11033-011-1065-y","article-title":"Down-regulation of beta3-integrin inhibits bone metastasis of small cell lung cancer","volume":"39","author":"Li","year":"2012","journal-title":"Mol. Biol. Rep."},{"issue":"4","key":"10.1016\/j.yexcr.2015.07.018_bib47","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1101\/gad.1758709","article-title":"Genetic and cell biological analysis of integrin outside-in signaling","volume":"23","author":"Legate","year":"2009","journal-title":"Genes Dev."},{"issue":"23","key":"10.1016\/j.yexcr.2015.07.018_bib48","doi-asserted-by":"crossref","first-page":"13298","DOI":"10.1073\/pnas.2336149100","article-title":"Src kinase activation by direct interaction with the integrin beta cytoplasmic domain","volume":"100","author":"Arias-Salgado","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"12","key":"10.1016\/j.yexcr.2015.07.018_bib49","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0960-9822(00)00537-6","article-title":"Integrin engagement suppresses RhoA activity via a c-Src-dependent mechanism","volume":"10","author":"Arthur","year":"2000","journal-title":"Curr. Biol."},{"issue":"1","key":"10.1016\/j.yexcr.2015.07.018_bib50","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.bone.2010.09.016","article-title":"Integrins and bone metastasis: integrating tumor cell and stromal cell interactions","volume":"48","author":"Schneider","year":"2011","journal-title":"Bone"},{"issue":"2","key":"10.1016\/j.yexcr.2015.07.018_bib51","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1006\/bbrc.1998.9180","article-title":"Activation of alphav beta3 integrin on human osteoclast-like cells stimulates adhesion and migration in response to osteopontin","volume":"249","author":"Faccio","year":"1998","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"33","key":"10.1016\/j.yexcr.2015.07.018_bib52","doi-asserted-by":"crossref","first-page":"24477","DOI":"10.1074\/jbc.M702877200","article-title":"CD98hc (SLC3A2) interaction with the integrin beta subunit cytoplasmic domain mediates adhesive signaling","volume":"282","author":"Prager","year":"2007","journal-title":"J. Biol. Chem."}],"container-title":["Experimental Cell Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014482715300483?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014482715300483?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T14:32:38Z","timestamp":1748529158000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014482715300483"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["S0014482715300483"],"URL":"https:\/\/doi.org\/10.1016\/j.yexcr.2015.07.018","relation":{},"ISSN":["0014-4827"],"issn-type":[{"value":"0014-4827","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of cilengitide in osteoclast maturation and behavior","name":"articletitle","label":"Article Title"},{"value":"Experimental Cell Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yexcr.2015.07.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}